Edgewise Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Edgewise Therapeutics, Inc. (Nasdaq: EWTX) on November 10, 2025. The filing reports a significant change in executive leadership, specifically the appointment of a new Chief Financial Officer (CFO) and the immediate retirement of the incumbent CFO. The company is currently advancing late-stage clinical development and preparing for commercialization.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and personnel changes.
Material Changes
- Departure of CFO: Michael Carruthers notified the company on November 10, 2025, of his intention to retire effective immediately. His departure is not the result of any disagreement with the company.
- Appointment of New CFO: Michael Nofi was appointed as Chief Financial Officer, effective November 10, 2025.
- Transition Plan: Mr. Carruthers is expected to remain an at-will employee until January 31, 2026, and subsequently provide consulting services until October 31, 2026, to ensure a smooth transition.
Compensation and Management Commentary
Mr. Nofi brings over 30 years of finance and accounting experience in the life sciences sector, including roles at SpringWorks Therapeutics, The Nature's Bounty Co., Acorda Therapeutics, Allergan plc, and Forest Laboratories. His compensation package includes:
- Base Salary: $465,000 annually.
- Cash Bonus: Target of 40% of annual base salary based on performance objectives.
- Stock Options: Grant of 262,500 shares under the 2024 Inducement Equity Incentive Plan. Vesting schedule: 25% on the one-year anniversary, with the balance vesting monthly thereafter over three years.
- Restricted Stock Units (RSUs): Award of 43,750 RSUs vesting in four equal annual installments.
- Severance: Participation in the Company's Executive Change in Control and Severance Plan.
Mr. Carruthers' outstanding equity awards will continue to vest in accordance with their terms during his consulting period. Specific hourly fees for his consulting services are to be determined in a future agreement.
Investor Verification Checklist
- Verify the full text of the Employment Offer Letter (Exhibit 10.1) for complete compensation terms and conditions.
- Monitor the upcoming Form 10-K for the year ended December 31, 2025, which will include the Letter Agreement and Consulting Agreement with Mr. Carruthers.
- Review the company's Definitive Proxy Statement on Schedule 14A (filed April 29, 2025) for details on the Executive Change in Control and Severance Plan applicable to Mr. Nofi.
- Confirm the status of the company's late-stage clinical trials and commercialization readiness as highlighted in the management commentary.